ArticleFrontiers in physiology2026
SIRT6 activation relieves neuropathic pain by restoring Nrf2 signaling and inhibiting NLRP3 inflammasome.
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Neuropathic pain arises from lesions or dysfunction within the somatosensory system, leading to chronic disability and scarce effective therapies. The NAD⁺-dependent deacetylase SIRT6 participates in aging and inflammatory responses, yet its involvement in neuropathic pain has remained unexplored. Using two selective SIRT6 activators-UBCS039 and MDL-800-in a rat model of chronic constriction injury (CCI), we asked whether pharmacological SIRT6 activation could ameliorate pain behaviors and, if so, through what molecular route. Methods: CCI surgery was performed in male Sprague-Dawley rats, and SIRT6 expression in the spinal dorsal horn was assessed post-operatively. From day 3 to day 9 after injury, rats received daily intraperitoneal injections of UBCS039 (20 mg/kg) or MDL-800 (10 mg/kg). On day 10, paw withdrawal thresholds (PWT) and paw withdrawal latencies (PWL) were measured. Spinal cord tissues were harvested for assessment of oxidative stress markers (TBARS, SOD, GSH-Px), pro-inflammatory cytokines (IL-1β, IL-18), NLRP3 inflammasome components (NLRP3, ASC, cleaved caspase-1), and Nrf2/HO-1 protein levels. An additional cohort received the Nrf2 inhibitor ML385 (30 mg/kg) 30 minutes before each MDL-800 dose to verify pathway specificity. Results: CCI markedly reduced SIRT6 mRNA and protein levels in the spinal dorsal horn (n=6 per group, P<0.001). Both UBCS039 and MDL-800 significantly elevated PWT and PWL (n=8, P<0.001), reduced TBARS content, restored SOD and GSH-Px activities (n=6, P<0.01), and suppressed IL-1β and IL-18 production at both transcript and protein levels. Western blotting revealed that SIRT6 activation inhibited NLRP3, ASC, and cleaved caspase-1 expression while reversing the CCI-induced decline of Nrf2 and HO-1. Co-administration of ML385 abolished these protective effects, rendering all measured parameters-including NLRP3 protein, cytokine levels, and pain thresholds-statistically indistinguishable from the untreated CCI group (P>0.05). Conclusion: Activating SIRT6 dampens neuropathic pain and NLRP3 inflammasome activation by restoring Nrf2 signaling. This positions SIRT6 as a previously unrecognized therapeutic target for neuropathic pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.